Login to Your Account



Financings Roundup


Wednesday, April 18, 2012
• Imaxio SA, of Lyon, France, said it raised €2.9 million (US$3.8 million) from principal shareholder Pradeyrol Developpement to speed up growth through two major R&D projects: IMX313, a vaccine-carrying protein platform set to start clinical development in 2013, and Spirolept, a vaccine against human leptospirosis expected to go before European authorities for approval starting in 2015.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription